Core Viewpoint - The company, iFlytek Medical, aims to demonstrate its investment value through its performance, despite the overall market uptrend in the Hang Seng Index and popular concept stocks [1] Financial Performance - For the first half of 2025, iFlytek Medical reported a revenue of 299 million yuan, representing a year-on-year growth of 30%, continuing a compound annual growth rate of 24.7% from 2022 to 2024 [1] - The company's gross margin remained stable at a high level of 51.5%, while the net loss rate significantly narrowed to 22%, improving by 15.5% year-on-year [1] Business Segments - Government segment revenue reached 140 million yuan, up 87% year-on-year, accounting for 47.4% of total revenue, with grassroots solutions growing by 52% and regional solutions by 178% [2] - The combined revenue from hospitals and patients was 156 million yuan, a year-on-year increase of 3.7%, making up 52.6% of total revenue [2] Product Matrix and Market Position - iFlytek Medical has developed a diversified product matrix for GBC (Government, Business, Consumer) scenarios, with its AI medical products leading the industry and achieving large-scale applications [2][3] - The core product "Smart Medical Assistant" has been implemented in over 69,700 grassroots institutions, completing over 1.01 billion AI-assisted diagnoses [3] Research and Development - The company invested 134 million yuan in R&D in the first half of 2025, accounting for 45% of its revenue, which has led to significant contributions from R&D outcomes [7] - iFlytek Medical's AI model, Spark Medical Model X1, has outperformed competitors in various medical tasks and has been recognized as a leader in the industry [5][7] Market Outlook - The AI medical market in China is projected to grow at a compound annual growth rate of 33.8% from 2019 to 2023, potentially reaching 315.7 billion yuan by 2033 [7] - The company is positioned to benefit from both high industry growth and supportive policies, with significant interest from institutional investors and a strong performance in the stock market [8]

Core Insights - The company reported a revenue of 299 million yuan for the first half of 2025, representing a year-on-year growth of 30.26% [1] - Gross profit reached 154 million yuan, with a year-on-year increase of 26.96% [1] - Despite ongoing losses, the net loss attributable to the parent company decreased to 74.09 million yuan, a reduction of 42.86% year-on-year [1] Business Segments - Government Segment: Revenue from grassroots solutions grew by 52.3% to 83.81 million yuan, with the core product "Smart Medical Assistant" covering 697 districts and counties and over 75,000 grassroots institutions, completing over 1.01 billion AI-assisted diagnostic suggestions [2] - Regional Solutions: Revenue surged by 178.1% to 57.63 million yuan, with AI infectious disease prevention solutions applied in multiple provinces [2] - Hospital Segment: Revenue from hospital solutions reached 52.86 million yuan, a decrease of 10% year-on-year, with the deployment of the company's large medical model in over 20 leading hospitals [2] - Consumer Segment: Patient management service revenue was 104 million yuan, up 10.1%, with the AI health assistant "Xunfei Xiaoyi" achieving over 24 million downloads and completing 140 million AI consultations [2]

Core Viewpoint - The company reported a significant increase in revenue and gross profit for the first half of 2025, driven by advancements in AI healthcare technology and supportive national policies [1]. Financial Performance - The company achieved an operating income of 299 million yuan, representing a year-on-year growth of 30.26% [1]. - The gross profit reached 154 million yuan, with a year-on-year increase of 26.96% [1]. Industry Context - The company is positioned to benefit from the "Digital China" and "Healthy China" strategies, with national policies promoting the integration of AI in healthcare [1]. - The company leverages its leading position in core medical model technology and extensive product coverage across the country to capitalize on the accelerating growth of the AI healthcare industry [1]. Future Strategy - The company plans to continue focusing on its development strategy, utilizing policy advantages to drive technological breakthroughs and deepen application scenarios in medical models [1]. - The company aims to provide higher quality medical services to residents and more efficient diagnostic tools for doctors [1]. Technological Advancements - Since the launch of the Xunfei Spark Medical Model in 2023, the company has expanded its technological advantages and achieved breakthroughs in multiple fields [1]. - In July 2025, the Xunfei Spark Medical Model underwent further upgrades, enhancing its capabilities and maintaining industry leadership in key medical task scenarios [1].

Core Insights - The company reported a strong performance in the first half of 2025, achieving a revenue of 299 million yuan, a year-on-year increase of 30%, and a gross profit of 154 million yuan, with a gross margin of 51.5% [1] Group 1: Financial Performance - Revenue for the first half of 2025 reached 299 million yuan, reflecting a 30% year-on-year growth [1] - Gross profit amounted to 154 million yuan, with a 27% increase compared to the previous year [1] - The gross margin remained stable at 51.5% [1] Group 2: Research and Development - The company invested 134 million yuan in R&D, accounting for 45% of its revenue [1] - The "Spark Medical Model" is the only large model trained on fully domestic computing power, achieving top rankings in the Medbench evaluation [1] - The model has demonstrated capabilities equivalent to chief physicians in major hospitals across various specialties [1] Group 3: Business Development - The company has established a collaborative business matrix covering government (G), hospital (B), and consumer (C) sectors [2] - Revenue from government solutions grew by 52%, while regional solutions surged by 178% [2] - The "Smart Medical Assistant" has been implemented in over 75,000 grassroots institutions, completing over 1.01 billion AI-assisted diagnoses [2] Group 4: Global Expansion - The company accelerated its global layout, launching the international version of the "Spark Medical Model" in Hong Kong [3] - The unique international status of Hong Kong facilitates the integration of local and English medical knowledge, enhancing the model's training data [3] Group 5: Long-term Strategy and Policy Support - The company is committed to using AI to serve the health sector in China, focusing on long-term development in smart healthcare [4] - National policies are increasingly promoting the integration of AI in healthcare, with specific initiatives aimed at enhancing AI applications in medical settings [4] - The company aims to leverage policy advantages and technological breakthroughs to improve healthcare services and tools for both residents and doctors [5]

Core Viewpoint - Xunfei Medical Technology reported its first interim performance post-IPO, showing revenue growth and a reduced net loss, indicating a positive trend in its financial health [1][2]. Financial Performance - For the first half of 2025, the company achieved a revenue of 299 million yuan, a year-on-year increase of 30.26% [1][2]. - The net profit attributable to the parent company was -74 million yuan, with losses narrowing by over 40% compared to the same period last year [1]. - Gross profit reached 154 million yuan, up 26.96% year-on-year, with a gross margin of 51.5%, slightly down from 52.9% in the previous year [1]. Revenue Breakdown - Revenue sources include grassroots solutions, regional solutions, hospital solutions, and patient management services [2]. - Grassroots solutions generated 83.81 million yuan, a 52.3% increase year-on-year, accounting for 28.1% of total revenue [2]. - Regional solutions saw explosive growth, with revenue of 57.625 million yuan, up 178.1% year-on-year, representing 19.3% of total revenue [2]. - Patient management services contributed 104 million yuan, a 10.1% increase year-on-year, making up 34.9% of total revenue [2]. - Hospital solutions recorded revenue of 52.862 million yuan, a decrease of 10.0% year-on-year, accounting for 17.7% of total revenue [3]. Industry Trends - The integration of AI in healthcare is a growing trend, driven by national policies promoting AI applications in medical settings [4]. - The government has emphasized the need for innovative technologies like remote medical services and AI-assisted diagnosis to enhance healthcare systems [4]. - Numerous medical companies are competing to integrate AI into their operations, facing challenges such as model accuracy and the need for practical value generation [4]. R&D Investment - The company invested 134 million yuan in R&D during the first half of 2025, representing 45% of its revenue [4]. Competitive Edge - The core product, Spark Medical Model, is the only large model trained on domestic computing power, ranking first in various medical reasoning and language understanding capabilities [5]. - The model's clinical diagnostic capabilities are comparable to those of chief physicians in top-tier hospitals, excelling in completeness, practicality, and readability [5].

Core Insights - Company reported a revenue of 299 million yuan for the first half of 2025, representing a year-on-year growth of 30% [1] - Gross profit reached 154 million yuan, with a growth of 27% year-on-year, resulting in a gross margin of 51.5% [1] - The net profit attributable to shareholders was -74 million yuan, significantly narrowing from -130 million yuan in the same period of 2024 [1] Government Solutions - Revenue from grassroots solutions grew by 52% year-on-year, while regional solutions surged by 178% [1] - The core product "Smart Medical Assistant" has been implemented in 697 districts and counties, covering over 75,000 grassroots institutions, with more than 1.01 billion AI-assisted diagnoses completed [1] - AI infectious disease prevention solutions have been scaled in several provinces including Anhui, Jiangxi, Zhejiang, Shaanxi, and Hunan [1] Hospital Solutions - AI solutions have been deployed in over 500 top-tier hospitals, including institutions like the First Affiliated Hospital of the University of Science and Technology of China and Peking Union Medical College Hospital [2] - The company has assisted nearly 20 hospitals in achieving electronic medical record level five and smart service level three evaluations [2] - Continuous iteration of the Spark Medical Model enhances efficiency and quality in precise diagnosis, scientific treatment, and systematic management for hospitals and doctors [2] Patient Management - Revenue from patient management increased by 10.1% year-on-year, with the AI health assistant "iFlytek Xiaoyi" completing 140 million AI consultations [2] - The company has extended its business into home care scenarios through a "hardware + service" model, creating a health management entry point for millions of users [2] R&D Investment - The company invested 134 million yuan in R&D, accounting for 45% of its revenue [2] - In March, the company launched the Spark Medical Model X1, which features "deep reasoning capabilities," and upgraded it in July to maintain its lead in general medical tasks [2] - The Spark Medical Model has been implemented in over 20 leading hospitals nationwide [2]

Core Insights - The company reported a revenue of 299 million yuan for the first half of 2025, representing a year-on-year growth of 30% [1] - The net profit attributable to the parent company was a loss of 74.086 million yuan, indicating a reduction in losses compared to the previous year [1] - Gross profit reached 154 million yuan, with a year-on-year increase of 27%, resulting in a gross margin of 51.5% [1] Revenue Breakdown - Revenue from grassroots solutions amounted to 83.812 million yuan, showing a year-on-year growth of 52% [1] - Revenue from regional solutions was 57.625 million yuan, with a significant year-on-year increase of 178% [1]

Xunfei Healthcare Technology Co., Ltd. 訊 飛 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 董事會提名委員會議事規則 第一章 總則 第一條 為進一步建立健全訊飛醫療科技股份有限公司（以下簡稱「公司」） 董事、總經理及其他高級管理人員的選任，完善公司治理結構，促進公司長遠 戰略目標的實現，根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《香 港聯合交易所有限公司證券上市規則》（以下簡稱「《香港聯交所上市規則》」）、 《訊飛醫療科技股份有限公司章程》（以下簡稱「《公司章程》」）及《訊飛醫療科技 股份有限公司董事會議事規則》的有關規定，公司設立董事會提名委員會，並 制定本議事規則。 第二條 提名委員會是董事會按照股東會決議設立的專門工作機構，對董 事會負責；主要負責對董事與高級管理人員的人選、選擇標準和程式進行討 論並提出建議。 第三條 本規則所稱董事是指在公司支取薪酬的董事；高級管理人員（高 管人員）是指董事會聘任的總經理及《公司章程》規定的其他高級管理人員。 第二 ...

訊 飛 醫 療 科 技 股 份 有 限 公 司 Xunfei Healthcare Technology Co., Ltd. 獨立非執行董事 汪揚教授 趙惠芳教授 談慶先生 董事會設有四個董事委員會。下表提供各董事所服務的該等委員會的成員資料。 | | 董事委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | 審計委員會 薪酬委員會 | | 提名委員會 | 環境、社會及 治理（ESG） | | | | | | 委員會 | | 陶曉東博士 | | | | M | | 劉慶峰博士 | | | C | C | | 趙志偉先生 | | M | | | | 段大為先生 | M | | | | | 汪揚教授 | M | | | M | | 趙惠芳教授 | C | C | M | | | 談慶先生 | | M | M | | （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 董事名單與其角色及職能 訊飛醫療科技股份有限公司董事（「董事」）會（「董事會」）成員載列如下： 執行董事 陶曉東博士 非執行董事 劉慶峰博士 趙志 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公司於2024年12月10日與科大訊飛（為及代表科大訊飛集團）訂立產品提供框 架協議。據此，本集團將向科大訊飛集團提供醫療器械產品，以在其自營線下 門店進行轉售及自用（如僱員福利）。產品提供框架協議的初始期限自本公司 上市日期（即2024年12月30日）起至2026年12月31日止。雙方的相關子公司將訂 立單獨的相關協議及╱或訂單，其將根據產品提供框架協議中規定的原則載 列具體條款及條件。 Xunfei Healthcare Technology Co., Ltd. 訊 飛 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2506） 修訂現有持續關連交易之年度上限 茲提述訊飛醫療科技股份有限公司（「本公司」）日期為2024年12月18日的招股章 程（「招股章程」），其中內容包括本公司與科大訊飛簽訂的持續關連交易框架 ...